A-SEEDS

A-SEEDS is a Japanese biotechnology startup focused on developing next-generation mRNA therapeutics through its proprietary RNA switch technology. Spun out from the University of Tokyo and Kyoto University, the company's platform enables the selective expression of therapeutic proteins by sensing specific intracellular microRNA signatures, ensuring that drugs are only activated within target cells like cancer cells. This high-precision approach is designed to enhance therapeutic windows by reducing off-target toxicity. A-SEEDS is currently advancing its pre-clinical pipeline with a primary focus on oncology and regenerative medicine applications. The company aims to overcome the limitations of conventional mRNA therapies by providing a more controlled and cell-specific delivery mechanism.